[Interferon alpha (IFNalpha) treatment for Sjögren's syndrome].
Nihon Rinsho
; 64(7): 1345-53, 2006 Jul.
Article
em Ja
| MEDLINE
| ID: mdl-16838655
ABSTRACT
IFNalpha is important for the defense against viral infection. By using a sensitive radioimmunoassay, we previously established the existence of endogenous IFNalpha in human. Serum IFNalpha, i.e., endogenous IFNalpha gradually increases with age, reaching the highest peak at young adults and then gradually declining with aging. We also found that serum IFNalpha levels were significantly low in the patients with Sjögren's syndrome. Subsequent treatment with a small dose 450 IU/day of orally administered IFNalpha significantly improved saliva secretion and the pathology of salivary glands of the patients as well. Since natural killer (NK) cell activity has been reported to be significantly decreased in the patients likely because of the decrease of IFNalpha, we may assume that correction of endogenous levels of IFNalpha by administering small amounts of IFNalpha will improve the vicious cycle in the pathology of the patients with Sjögren's syndrome.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Antivirais
/
Síndrome de Sjogren
/
Interferon-alfa
Tipo de estudo:
Etiology_studies
Limite:
Humans
Idioma:
Ja
Revista:
Nihon Rinsho
Ano de publicação:
2006
Tipo de documento:
Article